Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer [Yahoo! Finance]
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin. Khurram is well known in the hepatology community and has over 20 years of experience. After completing his general surgery residency at Seton Hall University, Khurram had several roles with increasing responsibility in biotechnology and pharmaceutical companies where he designed and led many clinical trials, several of which resulted in new drug approvals in the United States and other countries around the world. We have confidence in Kh
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business UpdateGlobeNewswire
- Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical OfficerGlobeNewswire
- Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20% [Yahoo! Finance]Yahoo! Finance
GALT
Earnings
- 8/13/24 - Miss
GALT
Analyst Actions
- 8/16/24 - HC Wainwright
GALT
Sec Filings
- 9/9/24 - Form 8-K
- 8/26/24 - Form 4
- 8/13/24 - Form 8-K
- GALT's page on the SEC website